Sezary Syndrome

• EMA approval · 2026-04-08
  EMA Authorised: Poteligeo (mogamulizumab) — Kyowa Kirin Holdings B.V.

  The EMA authorised Poteligeo (mogamulizumab) for Sezary Syndrome and Mycosis Fungoides. The designation includes orphan medicine status and …

• FDA approval · 2024-03-06
  FDA Approved: BEXAROTENE — Supplemental Application (Mylan Pharmaceuticals Inc.)

  FDA approved a supplemental application for bexarotene from Mylan Pharmaceuticals Inc., marking regulatory approval of the supplemental subm…

• FDA approval · 2015-09-14
  FDA Approved: TARGRETIN — Supplemental Application (Bausch Health US, LLC)

  The FDA approved a supplemental application for TARGRETIN (bexarotene) submitted by Bausch Health US, LLC.

• FDA approval · 2006-10-06
  FDA Approved: ZOLINZA — Original Application (Merck Sharp & Dohme LLC)

  The FDA approved Zolinza (vorinostat) under original NDA for cutaneous T-cell lymphoma, marking the first approval of this histone deacetyla…